4. Mức độ nhạy cảm với kháng sinh mới imipenem/relebactam của các chủng Klebsiella pneumoniae và Pseudomonas aeruginosa kháng carbapenem
Nội dung chính của bài viết
Tóm tắt
38 chủng Klebsiella pneumoniae sinh carbapenemase nhóm A và 42 chủng Pseudomonas aeruginosa sinh carbapenemase nhóm A hoặc đề kháng carbapenem theo cơ chế không sinh carbapenemase phân lập tại Bệnh viện Bạch Mai năm 2024 được xác định giá trị nồng độ ức chế tối thiểu (MIC) imipenem/relebactam bằng phương pháp Etest. Kết quả cho thấy mức độ nhạy cảm với imipenem/relebactam của các chủng K. pneumoniae là 92,1% (MIC50 = MIC90 = 0,5 µg/ml), của các chủng P. aeruginosa là 21,4% (MIC50 = MIC90 > 32 µg/ml). Imipenem/relebactam là một lựa chọn mới cho điều trị các nhiễm trùng do K. pneumoniae và P. aeruginosa kháng carbapenem nhưng nên sử dụng sau khi có kết quả kháng sinh đồ.
Chi tiết bài viết
Từ khóa
Klebsiella pneumoniae, Pseudomonas aeruginosa, imipenem/relebactam
Tài liệu tham khảo
1. World Health Organization. Antimicrobial resistance. Fact sheet. Published 2018. Accessed 2023. www.who.int/news-room/fact-sheets/detail/antibiotic-resistance. 2023.
2. Barrasa-Villar JI, Aibar-Remón C, Prieto-Andrés P, et al. Impact on morbidity, mortality, and length of stay of hospital-acquired infections by resistant microorganisms. Clin Infect Dis. 2017;15(65):644-652. doi.org/10.1093/cid/cix4 11.
3. Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;(18):318-327. doi.org/10.1016/S1473-3099(17)30753-3.
4. Yahav D, Giske CG, Graamatniece A, et al. New β-lactam- β-lactamase inhibitor combinations. Clin Microbiol Rev. 2021;34(1):e00115-20. doi.org/10.1128/CMR.0 0115-20.
5. Horcajada JP, Montero M, Oliver A, et al. Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev. 2019;32(4):e00031-19. doi: 10. 1128/CMR.00031-19.
6. Navon-Venezia S, Kondratyeva K, Carattoli A. Klebsiella pneumoniae: a major worldwide source and shuttle for antibiotic resistance. FEMS Microbiol Rev. 2017;41:252-275. doi.org/10.1093/FEMSRE/FUX013
7. Pitout JDD, Nordmann P, Poirel L. Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob Agents Chemother. 2015;59:5873-5884. doi.org/10.1 128/AAC.01019-15.
8. Botelho J, Grosso F, Peixe L. Antibiotic resistance in Pseudomonas aeruginosa - mechanisms, epidemiology and evolution. Drug Resist Update. 2019;44:100640. doi.org/10.1016/j.drup.2019.07.002.
9. Trần Hải Yến, Phạm Hồng Nhung, Nguyễn Tuấn Linh. Phân loại carbapenemase và kiểu cách đề kháng của chủng Klebsiella kháng carbapenem. Tạp chí Y học lâm sàng. 2020;119:115-120.
10. Nguyễn Tuấn Linh, Phạm Hồng Nhung, Trần Minh Châu. Nghiên cứu kiểu hình carbapenemase và tình hình đề kháng kháng sinh của các chủng Enterobacteriaceae kháng carbapenem. Tạp chí Y học lâm sàng. 2020;116:53-59.
11. Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother. 2010;54:969-976. doi.org/ 10.1128/AAC.01009-09.
12. MERCK. nonymous. Highlights of prescribing information. RECARBRIO™ (imipenem, cilastatin, and relebactam) for injection, for intravenous use. Published 2019. www.merck.com/product/usa/pi_circulars/r/rec arbrio/recarbrio_pi.pdf.
13. Janet A Hindler, Patricia J Simner, April Abbott, et al. Analysis and Presentation of cumulative antimicrobial susceptibility test data. 5th ed. CLSI guideline M39. Clinical and Laboratory Standards Institute. 2022.
14. James S Lewis II, Amy J Mathers, April M Bobenchik. Performance Standards for antimicrobial susceptibility testing. 34th Ed. CLSI suplement M100. Clinical and Laboratory Standards Institute. 2024.
15. Delgado-Valverde M, Portillo-Calderon I, Alcalde-Rico M, et al. Activity of imipenem/relebactam and comparators against KPC-producing Klebsiella pneumoniae and imipenem-resistant Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. 2024;43:445-457. /doi.org/10.1007/s10096-023-04735
16. Mashaly ME, Mashaly GE. Activity of imipenem/relebactam on Klebsiella pneumoniae with different mechnisms of imipenem non-susceptibility. Iran J Microbiol. 2021;13:785-792.
17. Ding L, Shen S, Chen J, et al. Klebsiella pneumoniae carbapenemase variants: the new threat to global public health. Cli Microbial Rev. 2023;36(4):e0000823. doi.org/10.1128/cmr.000 08-23.
18. Haidar G, Alkround A, Cheng S, et al. Association between the presence of aminoglycoside-modifing enzymes and in vitro activity of gentamicin, tobramycin, amikacin, and plazomicin against Klebsiella pneumoniae carbapenemase- and Extended-spectrum- β-lactamase-producing Enterocbacter species. Antimicrob Agents Chemother. 2016;60(9):5208-14. doi.org/10.1128/aac.0086 9-16
19. Bonnin RA, Bernabeu A, Emeraud C, et al. In vitro activity of imipenem-relebatcam, meropenem-vabobactam, ceftazidime-avibactam and comparators on carbapenem-resistant non-carbapenemase-producing Enterobacterales. Antibiotics. 2023;6:12:102. doi: 10.3390/antibiotics12010102.
20. Zhang H, Jia P, Zhu Y, et al. Susceptibility to imipenem/relebactam of Pseudomonas aeruginosa and Acinetobacter baumannii isolates from Chinese intra-abdominal, respiratory and urinary tract infections: SMART 2015 to 2018. Infect Drug Resist. 2021;14:3509-3518. doi. org/ 10. 2147/ IDR. S3255 20.
2. Barrasa-Villar JI, Aibar-Remón C, Prieto-Andrés P, et al. Impact on morbidity, mortality, and length of stay of hospital-acquired infections by resistant microorganisms. Clin Infect Dis. 2017;15(65):644-652. doi.org/10.1093/cid/cix4 11.
3. Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;(18):318-327. doi.org/10.1016/S1473-3099(17)30753-3.
4. Yahav D, Giske CG, Graamatniece A, et al. New β-lactam- β-lactamase inhibitor combinations. Clin Microbiol Rev. 2021;34(1):e00115-20. doi.org/10.1128/CMR.0 0115-20.
5. Horcajada JP, Montero M, Oliver A, et al. Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev. 2019;32(4):e00031-19. doi: 10. 1128/CMR.00031-19.
6. Navon-Venezia S, Kondratyeva K, Carattoli A. Klebsiella pneumoniae: a major worldwide source and shuttle for antibiotic resistance. FEMS Microbiol Rev. 2017;41:252-275. doi.org/10.1093/FEMSRE/FUX013
7. Pitout JDD, Nordmann P, Poirel L. Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob Agents Chemother. 2015;59:5873-5884. doi.org/10.1 128/AAC.01019-15.
8. Botelho J, Grosso F, Peixe L. Antibiotic resistance in Pseudomonas aeruginosa - mechanisms, epidemiology and evolution. Drug Resist Update. 2019;44:100640. doi.org/10.1016/j.drup.2019.07.002.
9. Trần Hải Yến, Phạm Hồng Nhung, Nguyễn Tuấn Linh. Phân loại carbapenemase và kiểu cách đề kháng của chủng Klebsiella kháng carbapenem. Tạp chí Y học lâm sàng. 2020;119:115-120.
10. Nguyễn Tuấn Linh, Phạm Hồng Nhung, Trần Minh Châu. Nghiên cứu kiểu hình carbapenemase và tình hình đề kháng kháng sinh của các chủng Enterobacteriaceae kháng carbapenem. Tạp chí Y học lâm sàng. 2020;116:53-59.
11. Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother. 2010;54:969-976. doi.org/ 10.1128/AAC.01009-09.
12. MERCK. nonymous. Highlights of prescribing information. RECARBRIO™ (imipenem, cilastatin, and relebactam) for injection, for intravenous use. Published 2019. www.merck.com/product/usa/pi_circulars/r/rec arbrio/recarbrio_pi.pdf.
13. Janet A Hindler, Patricia J Simner, April Abbott, et al. Analysis and Presentation of cumulative antimicrobial susceptibility test data. 5th ed. CLSI guideline M39. Clinical and Laboratory Standards Institute. 2022.
14. James S Lewis II, Amy J Mathers, April M Bobenchik. Performance Standards for antimicrobial susceptibility testing. 34th Ed. CLSI suplement M100. Clinical and Laboratory Standards Institute. 2024.
15. Delgado-Valverde M, Portillo-Calderon I, Alcalde-Rico M, et al. Activity of imipenem/relebactam and comparators against KPC-producing Klebsiella pneumoniae and imipenem-resistant Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. 2024;43:445-457. /doi.org/10.1007/s10096-023-04735
16. Mashaly ME, Mashaly GE. Activity of imipenem/relebactam on Klebsiella pneumoniae with different mechnisms of imipenem non-susceptibility. Iran J Microbiol. 2021;13:785-792.
17. Ding L, Shen S, Chen J, et al. Klebsiella pneumoniae carbapenemase variants: the new threat to global public health. Cli Microbial Rev. 2023;36(4):e0000823. doi.org/10.1128/cmr.000 08-23.
18. Haidar G, Alkround A, Cheng S, et al. Association between the presence of aminoglycoside-modifing enzymes and in vitro activity of gentamicin, tobramycin, amikacin, and plazomicin against Klebsiella pneumoniae carbapenemase- and Extended-spectrum- β-lactamase-producing Enterocbacter species. Antimicrob Agents Chemother. 2016;60(9):5208-14. doi.org/10.1128/aac.0086 9-16
19. Bonnin RA, Bernabeu A, Emeraud C, et al. In vitro activity of imipenem-relebatcam, meropenem-vabobactam, ceftazidime-avibactam and comparators on carbapenem-resistant non-carbapenemase-producing Enterobacterales. Antibiotics. 2023;6:12:102. doi: 10.3390/antibiotics12010102.
20. Zhang H, Jia P, Zhu Y, et al. Susceptibility to imipenem/relebactam of Pseudomonas aeruginosa and Acinetobacter baumannii isolates from Chinese intra-abdominal, respiratory and urinary tract infections: SMART 2015 to 2018. Infect Drug Resist. 2021;14:3509-3518. doi. org/ 10. 2147/ IDR. S3255 20.